---
title: "BiomX sets up $2,000,000 credit line from Mandragola"
url: "https://aibio.space/news/biomx-sets-up-2-000-000-credit-line-mandragola-12-percent-notes/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-05-13"
section: "Debt Financing"
source: "https://www.sec.gov/Archives/edgar/data/1739174/000121390026065850/ea0293750-8k_biomx.htm"
summary: "Mandragola Ltd is the lender under a credit line that issues 12% convertible promissory notes for each advance. Mandragola also received a five-year warran"
---

By the aibio.space news desk.

Sources

- [BiomX Inc. 8-K (2026-06-05)](https://www.sec.gov/Archives/edgar/data/1739174/000121390026065850/ea0293750-8k_biomx.htm)

2026-05-13

# BiomX sets up $2,000,000 credit line from Mandragola with 12% notes

Mandragola Ltd is the lender under a credit line that issues 12% convertible promissory notes for each advance. Mandragola also received a five-year warrant.

## Key facts

- **News type**: Debt Financing

- **Primary source**: [BiomX Inc. 8-K (2026-06-05)](https://www.sec.gov/Archives/edgar/data/1739174/000121390026065850/ea0293750-8k_biomx.htm)

*Office towers against a dusk sky. CC0, via rawpixel. The picture shows the field, not the companies named.*

BiomX Inc. entered into a Line of Credit Agreement dated May 13, 2026 with Mandragola Ltd, a company formed under the laws of Israel. The revolving line is up to $2,000,000, available to the company or any operating subsidiary. Each advance is evidenced by a convertible promissory note with simple annual interest of 12%.

The notes convert into common stock at the closing price on the trading day before the conversion notice. Earlier advances Mandragola made for the company's acquisition of a controlling stake in Dr. Frucht Systems Ltd. count as advances under the line.

On June 2, 2026, BiomX issued 1,013,637 restricted shares to three individual assignees on partial conversion of a note originally issued to Mandragola, covering approximately $379,000 in principal. The company then had 11,160,153 shares outstanding.

As additional consideration, the company issued Mandragola a five-year warrant for up to 2,000,000 shares of common stock at $12.00 per share, with a cashless exercise feature. Shares under the warrant need stockholder approval under NYSE American rules. Mandragola is the only lender named, and the filing names no placement agent or advisor.

[Report an error](https://aibio.space/reputation/#correction)

## More in Debt Financing

Debt Financing

### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/)

Oct 30, 2026

Debt Financing

### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/)

Oct 30, 2026

Debt Financing

### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/)

Oct 29, 2026

---
Source page: https://aibio.space/news/biomx-sets-up-2-000-000-credit-line-mandragola-12-percent-notes/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BiomX sets up $2,000,000 credit line from Mandragola", 2026-05-13, https://aibio.space/news/biomx-sets-up-2-000-000-credit-line-mandragola-12-percent-notes/